

**IN THE CLAIMS:**

Claims 1-93. (canceled).

94. (Currently amended) A transgenic mouse comprising a ~~recombinant cell~~,  
~~wherein said cell comprises a~~ an exogenous nucleotide sequence, wherein said exogenous  
nucleotide sequence comprises a Group I intron encoded endonuclease recognition site,  
wherein the site is selected from the group consisting of an I-*SceIV* site, an I-  
*CsmI* site, I-*PanI* site, I-*SceII* site, an I-*CeuI* site, an I-*PpoI* site, an I-*SceIII* site, an I-*CreI*  
site, an I-*TevI* site, an I-*TevII* site, an I-*TevIII* site, and an I-*SceI* site.

95. (Previously presented) The transgenic mouse of claim 94, wherein the site is  
an I-*SceIV* site.

96. (Previously presented) The transgenic mouse of claim 94, wherein the site is  
an I-*CsmI* site.

97. (Previously presented) The transgenic mouse of claim 94, wherein the site is  
an I-*PanI* site.

98. (Previously presented) The transgenic mouse of claim 94, wherein the site is  
an I-*SceII* site.

99. (Previously presented) The transgenic mouse of claim 94, wherein the site is  
an I-*CeuI* site.

100. (Previously presented) The transgenic mouse of claim 94, wherein the site  
is an I-*PpoI* site.

101. (Previously presented) The transgenic mouse of claim 94, wherein the site  
is an I-*SceIII* site.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

102. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-CreI site.

103. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-TevI site.

104. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-TevII site.

105. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-TevIII site.

106. (Previously presented) The transgenic mouse of claim 94, wherein the site is an I-SceI site.

107. (Currently amended) A method of culturing transgenic cells comprising the steps of:

(a) providing a cell from a transgenic mouse comprising an exogenous nucleotide sequence, wherein said exogenous nucleotide sequence comprises in which at least one Group I intron encoded endonuclease recognition site is inserted at a unique location in a chromosome of said cell,

wherein the site is selected from the group consisting of an I-SceIV site, an I-CsmI site, I-PanI site, I-SceII site, an I-CeuI site, an I-Ppol site, an I-SceIII site, an I-CreI site, an I-TevI site, an I-TevII site, an I-TevIII site, and an I-SceI site; and

(b) culturing said cell under conditions that allow growth of said cell.

108. (Previously presented) The method of claim 107, wherein the site is an I-SceIV site.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

109. (Previously presented) The method of claim 107, wherein the site is an I-*CsmI* site.
110. (Previously presented) The method of claim 107, wherein the site is an I-*PanI* site.
111. (Previously presented) The method of claim 107, wherein the site is an I-*SceII* site.
112. (Previously presented) The method of claim 107, wherein the site is an I-*CeuI* site.
113. (Previously presented) The method of claim 107, wherein the site is an I-*PpoI* site.
114. (Previously presented) The method of claim 107, wherein the site is an I-*SceIII* site.
115. (Previously presented) The method of claim 107, wherein the site is an I-*CreI* site.
116. (Previously presented) The method of claim 107, wherein the site is an I-*TevI* site.
117. (Previously presented) The method of claim 107, wherein the site is an I-*TevII* site.
118. (Previously presented) The method of claim 107, wherein the site is an I-*TevIII* site.
119. (Previously presented) The method of claim 107, wherein the site is an I-*SceI* site.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)